Chang-Claude J - Search Results

1

Role of genetic polymorphisms and ovarian cancer susceptibility.

Fasching PA, Gayther S, Pearce L, Schildkraut JM, Goode E, Thiel F, Chenevix-Trench G, Chang-Claude J, Wang-Gohrke S, Ramus S, Pharoah P, Berchuck A; OCAC (Ovarian Cancer Association Consortium). Fasching PA, et al. Mol Oncol. 2009 Apr;3(2):171-81. doi: 10.1016/j.molonc.2009.01.008. Epub 2009 Feb 4. Mol Oncol. 2009. PMID: 19383379 Free PMC article. Review.

2

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, et al. Ford D, et al. Am J Hum Genet. 1998 Mar;62(3):676-89. doi: 10.1086/301749. Am J Hum Genet. 1998. PMID: 9497246 Free PMC article.

3

Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50.

Wang-Gohrke S, Chang-Claude J, Becher H, Kieback DG, Runnebaum IB. Wang-Gohrke S, et al. Cancer Res. 2000 May 1;60(9):2348-50. Cancer Res. 2000. PMID: 10811106

4

A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability.

Healey CS, Dunning AM, Teare MD, Chase D, Parker L, Burn J, Chang-Claude J, Mannermaa A, Kataja V, Huntsman DG, Pharoah PD, Luben RN, Easton DF, Ponder BA. Healey CS, et al. Nat Genet. 2000 Nov;26(3):362-4. doi: 10.1038/81691. Nat Genet. 2000. PMID: 11062481

5

Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.

Wang-Gohrke S, Chang-Claude J. Wang-Gohrke S, et al. J Natl Cancer Inst. 2001 Nov 7;93(21):1657-9. doi: 10.1093/jnci/93.21.1657. J Natl Cancer Inst. 2001. PMID: 11698574 No abstract available.

6

Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years.

Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J. Wang-Gohrke S, et al. Pharmacogenetics. 2002 Apr;12(3):269-72. doi: 10.1097/00008571-200204000-00012. Pharmacogenetics. 2002. PMID: 11927843

7

A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer.

Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, Kataja V, Pharoah PD, Easton DF, Ponder BA, Metcalfe JC. Dunning AM, et al. Cancer Res. 2003 May 15;63(10):2610-5. Cancer Res. 2003. PMID: 12750287

8

Integrin beta3 Leu33Pro polymorphism and breast cancer risk: a population-based case-control study in Germany.

Wang-Gohrke S, Chang-Claude J. Wang-Gohrke S, et al. Breast Cancer Res Treat. 2004 Dec;88(3):231-7. doi: 10.1007/s10549-004-0782-5. Breast Cancer Res Treat. 2004. PMID: 15609125

9

Alcohol dehydrogenase 1B (ADH1B) genotype, alcohol consumption and breast cancer risk by age 50 years in a German case-control study.

Lilla C, Koehler T, Kropp S, Wang-Gohrke S, Chang-Claude J. Lilla C, et al. Br J Cancer. 2005 Jun 6;92(11):2039-41. doi: 10.1038/sj.bjc.6602608. Br J Cancer. 2005. PMID: 15886702 Free PMC article.

10

Re: Integrin beta3 Leu33Pro homozygosity and risk of cancer.

Wang-Gohrke S, Chang-Claude J. Wang-Gohrke S, et al. J Natl Cancer Inst. 2005 May 18;97(10):778-9; author reply 779-80. doi: 10.1093/jnci/dji135. J Natl Cancer Inst. 2005. PMID: 15900047 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

922 results

Search Page